Overview
Study of HS235 in Obese Participants with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction
Description
A Phase 1b/2, Multicenter, Double-Blind, Placebo-Controlled, Multiple Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS235 in Obese Participants with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction
Eligibility
Inclusion Criteria:
Participants are eligible to be included in the study only if they meet at least all the following criteria:
- Male or female, ≥ 18 years of age.
- \[Sub-population A only - using a remote PAP sensor\]- Ambulatory PAP monitoring (e.g., CardioMEMS™ HF System or Cordella™ HF System) implanted in the course of standard of care at least 90 days before Screening.
Hemodynamic evidence of PH with:
- mPAP ≥ 25 mm Hg, as measured in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization AND,
- dPAP ≥ 15 mm Hg, as measured in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization.
- \[Sub-population B only - without a remote PAP sensor\]
Hemodynamic evidence of PH based on the presence of all the following RHC parameters obtained during the Screening period, prior to randomization:
- PVR ≥ 240 dyn\*sec/cm5 or ≥ 3 WU, and
- mPAP \> 20 mmHg, and
- PAWP \> 15 mmHg but \< 30 mmHg, and
- dPAP ≥ 15 mmHg.
- Established diagnosis of HFpEF with left ventricular ejection fraction (LVEF) ≥ 45 % as measured by echocardiography during Screening and and no documented LVEF \< 45% during the 2 years preceding Screening..
- New York Heart Association (NYHA) class II or III heart failure symptoms.
- Stable diuretic regimen during the screening period.
- Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) \< 90 at screening.
- 6-minute walking distance (6MWD) ≥ 100 m at screening.
- Body mass index ≥ 30 to ≤ 50 kg/m2 and Body weight ≤140 kg.
- Ability to adhere to study visit schedule and understand and comply with all protocol requirements.
Exclusion Criteria:
- Hospitalization for any worsening medical condition or major surgery within 4 weeks prior to screening.
- Occurrence of an acute coronary syndrome, percutaneous coronary intervention, or cardiac surgery within 90 days prior to Screening.
- Implantation of a cardiac resynchronization therapy (CRT) device within 90 days before screening.
- Planned cardiovascular revascularization or planned implantation of CRT device.
- History of heart transplant or on heart transplant list.
- History of serious or life-threatening cardiac arrhythmia within 90 days prior to screening.
- Systemic hypotension or uncontrolled systemic hypertension.
- History of Pericardial constriction or hypertrophic cardiomyopathy.
- History of significant valvular stenosis or regurgitation.
- Participants with a pneumonectomy or more than moderate Chronic Obstructive Pulmonary Disease (COPD) or mild interstitial lung disease (ILD) or mild obstructive sleep apnea (OSA).


